[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chondral-defect\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chondral-defect":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,49,78,109,138,158,188,219,241],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100330956","phase-3-a-study-of-maci-in-patients-aged-10-to-17-years-with-symptomatic-chondral-or-osteochondral-defects-of-the-knee-100330956",false,"NCT03588975","A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee","A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee","PEAK","Inclusion Criteria:\n\n* Symptomatic cartilage or osteochondral defects\n* One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and\u002For trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).\n\n  1. Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.\n  2. Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.\n* At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and\u002For the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.\n* Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.\n* Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.\n* Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.\n* Written informed consent\n\nExclusion Criteria:\n\n* Any surgery on the target knee joint within 6 months prior to Screening (not including diagnostic arthroscopy)\n* Previous investigational drug or device use within 3 months prior to Screening\n* Avascular necrosis of the target knee (other than potential OCD lesion to be treated)\n* Participants with uninvolved open growth plates where the surgery necessitates crossing the growth plate, or where the depth of the lesion crosses the growth plate\n* ICRS Grade III or IV chondral or unsalvageable osteochondral defects located on the tibia or any lesion that is bipolar to the index lesion\n* Malalignment requiring concurrent osteotomy to correct tibial-femoral or patella-femoral alignment (prior guided growth treatment is not exclusionary)\n* Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target knee joint\n* Concomitant inflammatory disease or other conditions that affects the joints (eg, rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis)\n* Known history of septic arthritis in the index knee joint\n* Current malignancy or treatment for malignancy within the past 5 years\n* Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin\n* Females who are pregnant or lactating\n* Participants who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:\n\n  * Any condition that has potential for negatively impacting intra or postoperative course\n  * Conditions that limit compliance with rehabilitation program\n  * Any condition that has potential for significantly limiting participant's ability to assess postoperative knee function\n  * Any condition, psychiatric or otherwise, that would preclude informed consent\u002Fassent, consistent follow-up, or compliance with any aspect of the study\n  * Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance","ALL","10 Years","17 Years",{"count":21,"type":22},45,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.",[28,29,30,31],"Chondral Defect","Osteochondritis Dissecans (OCD)","Articular Cartilage Defect","Articular Cartilage Disorder of Knee",[33,34,35],"OCD","cartilage","cartilage defect","RECRUITING","2026-06-19",{"date":39,"type":40},"2026-06-24","ACTUAL",{"date":42,"type":40},"2018-10-24",{"date":44,"type":22},"2030-02",{"name":46,"class":47},"Vericel Corporation","INDUSTRY",12,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":19,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100586427","phase-3-a-study-of-maci-in-patients-aged-17-to-65-years-with-symptomatic-chondral-or-osteochondral-defects-of-the-ankle-100586427","NCT06915233","A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle","A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients With Symptomatic Chondral or Osteochondral Lesions of the Talus (MASCOT)","MASCOT","Inclusion Criteria:\n\n1. Age 17 to 65 at the time of planned randomization visit (Visit 2).\n2. One or more symptomatic chondral or osteochondral lesion\u002Fs as defined by FAOS Pain score ≤ 50 and FAOS Function (SRA) score ≤ 50.\n3. International Cartilage Repair Society (ICRS) Score Grade 3 or 4 chondral or osteochondral lesion\u002Fs located on the talus with or without cysts, including shoulder lesions (lesions on the talar neck), and amenable to treatment with the surgical procedure specified at randomization.\n4. At least 1 lesion ≥ 1.2 cm².\n5. Written informed consent and assent (as applicable) per Institutional Review Board (IRB) requirements.\n6. Participant will refrain from using Non-steroidal Anti-inflammatory Drugs (NSAIDS) for 12 weeks post-study treatment. (Post-surgical use of low-dose aspirin for clot prevention is acceptable).\n7. Participant will restrict pain medication to over-the-counter analgesics (NSAIDs or acetaminophen\u002Fparacetamol) after 12 weeks post-study treatment.\n8. Participant must have Hematocrit ≥30.0%; White Blood Cell count ≤14,000 cells\u002FμL; Platelet Count ≥50,000 platelets\u002FμL; Creatinine ≤2.0 mg\u002FdL; and International Normalized Ratio (INR) ≤1.6.\n\nExclusion Criteria:\n\n1. Lesions with an underlying bony defect depth of \\> 5 mm.\n2. Any surgery on the target joint within 24 weeks prior to Visit 1 (not including diagnostic ankle arthroscopy).\n3. Previous investigational drug, biologic or device use within 12 weeks prior to Visit.\n4. Avascular necrosis of the target ankle.\n5. Symptomatic musculoskeletal conditions in the lower limbs that could impede measurement of efficacy for the target ankle joint.\n6. Participant with \"kissing lesions\" (bipolar lesions, involving both the tibia and talus), or with bilateral lesions in both ankles.\n7. Participant with lesions that require an osteotomy procedure to allow for MACI implantation as determined at the time of ankle arthroscopy (Visit 2).\n8. Concomitant systemic inflammatory diseases or other conditions that affect the joints (e.g., rheumatoid arthritis, metabolic bone disease, psoriasis, symptomatic chondrocalcinosis).\n9. History of advanced or severe osteoarthritis of the ankle as determined by prior surgical history confirming no joint space (i.e., \"bone on bone\") or radiographic evidence of Modified Kellgren-Lawrence Grade 4 arthritis (i.e., osteophytes on lateral and medial malleoli and at the tibiotalar joint margins, narrowing of the joint space width \\> 50%, and tibiotalar sclerosis), Van Dijk Grade III (i.e., total or subtotal destruction of the joint space) or the equivalent.\n10. Known history of septic arthritis in the target ankle joint within 1 year prior to Visit 1.\n11. Current malignancy or treatment for malignancy within the past 5 years prior to Visit 1, excluding non-melanoma skin cancer.\n12. Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of porcine or bovine origin.\n13. Females who are pregnant or lactating.\n14. Patients who, in the opinion of the Investigator, have significant medical or psychosocial problems that warrant exclusion. Examples of significant problems included but are not limited to:\n\n    1. Any condition that has potential for negatively impacting intra- or postoperative course (e.g., uncontrolled diabetes, heavy smoking). - Uncontrolled diabetes is defined as hemoglobin A1c (HbA1c) ≥8.0% and\u002For fasting plasma glucose \\>250 mg\u002FdL (13.9 mmol\u002FL) within the last 90 days prior to Screening Visit 1 - Heavy smoking is defined as current smoker with use of ≥20 cigarettes per day (≥1 pack\u002Fday) at the time of Screening Visit 1.\n    2. Conditions that limit compliance with rehabilitation program.\n    3. Any condition that has potential for significantly limiting participant's ability to assess postoperative ankle function.\n    4. Any condition, psychiatric or otherwise, that would preclude informed consent\u002Fassent, consistent follow-up, or compliance with any aspect of the clinical trial.\n    5. Participant is currently abusing drugs or alcohol or, in the opinion of the Investigator, at high risk for poor compliance.\n    6. Any abnormal screening blood work that the Investigator deems clinically significant in addition to the parameters delineated in Inclusion Criterion #8.\n15. Injection of hyaluronic acid (HA), platelet-rich plasma (PRP), and\u002For corticosteroids in the target ankle within 90 days prior to Visit 1.","65 Years",{"count":59,"type":22},309,[25],"The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus.",[28,30],[64,65,66,67,68],"Bone Diseases","Musculoskeletal Diseases","Connective Tissue Diseases","Osteochondritis","Cartilage Diseases","2026-05-21",{"date":71,"type":40},"2026-05-27",{"date":73,"type":22},"2026-05",{"date":75,"type":22},"2030-07",{"name":46,"class":47},4,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":108},"100586938","the-biomechanical-outcomes-of-autologous-chondrocyte-implantation-100586938","NCT06921889","The Biomechanical Outcomes of Autologous Chondrocyte Implantation","Investigating the Biomechanical and Functional Outcomes of Autologous Chondrocyte Implantation: A Multi-centre Study","Inclusion Criteria:\n\n* Diagnosis of a chondral injury to the knee by a consultant orthopaedic surgeon Participants must have this diagnosis, else they are not eligible for ACI surgery.\n* Listed for ACI for a chondral injury by a consultant orthopaedic surgeon Participants must be listed for ACI, as this is the treatment of interest in this research study\n* Over 18 years old Participants must be legally capable of providing informed consent for the study.\n\nExclusion Criteria:\n\n* Listed for any treatment other than ACI Participants must be listed for ACI, as this is the treatment of interest in this research study\n* Under 18 years old. Participants must be legally capable of providing informed consent for the study.","18 Years",{"count":87,"type":22},47,"OBSERVATIONAL","Injury to the knee can damage the lining of the knee's bones, called cartilage. Cartilage injuries cause pain and limit movement, making activities like walking, playing sports, and working difficult.\n\nCartilage cannot repair itself well, so surgery is often needed to repair it. People who have cartilage repair surgery want to return to normal activities after their operation. Doctors and scientists know the operation can reduce pain, but do not fully understand how it affects movement.\n\nThis research will help us see if knee function gets better after cartilage repair surgery. The results will help doctors and patients understand what to expect from the surgery. It could also uncover common problems after surgery that could be fixed with physiotherapy.\n\nThis research is important because untreated cartilage injuries can develop into arthritis later in life. Arthritis is a painful lifelong condition that could be prevented by effectively treating the cartilage injury.\n\nIn this study, adult patients who are waiting to have a type of cartilage repair surgery called 'autologous chondrocyte implantation' (ACI) at one of 7 hospitals will be invited to take part in the study by their surgeon. Patients who decide to take part will be invited to two appointments at their own hospital, where assessments of their knee function will be performed. The tests will assess the knee's movement, and the patient's balance and walking abilities. The first research appointment will take place before the operation, and the second and final appointment will take place 6-months after surgery. The results of this study will help us understand how knee function changes after cartilage repair surgery.\n\nThe study will take place across 7 ACI centres in England, and is funded by Orthopaedic Research UK and the British Association for Surgery of the Knee.",[28],[92,93,94,95,96,97],"Chondral defect","Cartilage repair","Knee","Autologous chondrocyte implantation","Biomechanical outcome","Gait","2026-05-01",{"date":100,"type":40},"2026-05-07",{"date":102,"type":40},"2024-04-22",{"date":104,"type":22},"2026-07-13",{"name":106,"class":107},"University of Manchester","OTHER",7,{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":23,"phases":120,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":137},"100489352","study-comparing-two-methods-for-the-treatment-of-large-chondral-and-osteochondral-defects-of-the-knee-100489352","NCT05651997","Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee","Randomized Study Comparing Two Methods for the Treatment of Large Chondral and Osteochondral Defects of the Knee: Augmented Microfracture Technique vs. 3rd Generation of ACI","Inclusion Criteria:\n\n* Patients aged between 15-50 years\n* Symptomatic chondral and osteochondral defect, grade III and IV according to the ICRS classification, and size between 2.5 and 15 cm2\n* Failure of a conservative treatment\n* Patient in good general condition, documented by an ASA score ≤ 2 (American Society of Anesthesiologists)\n* Patient considered compliant and able to participate in rehabilitation and pre- and post-operative follow-up\n* Consent to participate in the study\n\nExclusion Criteria:\n\n* All inflammatory and synovial pathologies\n* Diffuse or mirror lesions\n* An unfavorable biomechanical environment\n* Obesity grade II or higher, with a BMI\\>35 kg\u002Fm2\n* Active smoking\u002F active drug dependency (hard drugs)\n* Poor compliance\n* The patient is already part of another clinical trial that may compromise the present study\n* Vulnerable populations (except minors aged 15-18 years)\n* Presence of open growth plate (15-18 years)\n* Pregnancy or planned pregnancy during the study (MRI-related contra-indication)\n* Proven allergy to penicillin and gentamicin (for MACT group) and porcine collagen (for both groups)\n\nFor final inclusion, an additional exclusion criteria will be assessed after randomization:\n\n\\- Positive to HIV, HBV, HCV, syphilis.","15 Years","50 Years",{"count":119,"type":22},80,[121],"NA","The major objective of this study is to evaluate the efficacy of the MACT versus the AMT for the treatment of large cartilage defects in patellofemoral and femorotibial injuries.",[30,28,67],[125,126],"Cellular therapy","Human articular chondrocytes","NOT_YET_RECRUITING","2026-03-10",{"date":130,"type":40},"2026-03-12",{"date":132,"type":22},"2026-12",{"date":134,"type":22},"2032-06-01",{"name":136,"class":107},"Centre Hospitalier Universitaire Vaudois",2,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":116,"maxAge":117,"enrollmentInfo":145,"targetDuration":4,"studyType":23,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":157},"100385267","introduction-of-aci-for-cartilage-repair-100385267","NCT04296487","Introduction of ACI for Cartilage Repair","Introduction of Autologous Chondrocyte Implantation Procedure for the Treatment of Chondral Defect in the Knee","Inclusion Criteria:\n\n1. Age between 15 and 50.\n2. Lesions classified as ICRS Grade III or IV and smaller than 15 cm2\n3. Lesions that have failed prior therapy (conservative or surgical treatment ≥ six months)\n4. Subjects who understand and sign the consent form for this study\n\nExclusion Criteria:\n\n1. Body mass index (BMI) of 35 or more\n2. Osteoarthritis or rheumatoid arthritis\n3. Diffuse lesion\n4. Uncorrected mal-alignment, ligamentous instability, or meniscal tear\n5. Presence of growth cartilage (15-18 years old)\n6. Active smoking or drug consumption\n7. Women who are pregnant\n8. Positive serology for HIV-1 or HIV-2, Hepatitis B and C and syphilis\n9. Proven allergy to porcine collagen, penicillin and gentamicin\n10. Poor compliance",{"count":146,"type":22},218,[121],"This study was aimed to evaluate effectiveness and safety of autologous chondrocyte suspension for treatment of knee articular cartilage defects.",[30,28,67],{"date":151,"type":40},"2026-03-11",{"date":153,"type":40},"2017-09-01",{"date":155,"type":22},"2030-09",{"name":136,"class":107},1,{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":4,"eligibilityCriteria":164,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":165,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":167,"conditions":168,"keywords":173,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":157},"100355529","use-of-bmac-with-hip-arthroscopy-treatment-of-fai-and-labral-tear-100355529","NCT03909139","Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear","Prospective PROMs Outcomes in Arthroscopic Acetabular Labral Repair With and Without Application of Platelet-Rich Plasma (PRP) Harvested From the Body of the Ilium","Inclusion Criteria and Rationale:\n\n1. Age 18 or older: patients of any age have the capacity to potentially benefit from labral repair\n2. Symptoms consistent with a tear of the acetabular labrum (i.e., catching, clicking, popping, pain with sitting, episodic pain, pain with hip flexion, adduction, and\u002For internal rotation): asymptomatic labral tears do exist in the general population however there is not definitive evidence to suggest treatment of asymptomatic tears is beneficial.\n3. Symptoms not due to some other acute process in or around the hip (including septic arthritis, osteonecrosis, hemarthrosis, iliotibial band syndrome, fractures of the femoral neck or head, fractures of the acetabulum, greater trochanteric pain syndrome, sacroiliac joint pain, piriformis syndrome, low back pain associated with hip pain and not knee nor acute low back injury): certain conditions are not treatable by either arthroscopy or physical therapy. Some of these conditions can be managed with physical therapy but not arthroscopy.\n4. Availability of hip radiographs and magnetic resonance imaging (MRI and\u002For MRA): needed to assess eligibility\n5. Evidence of labral tear on MRI and\u002For MRA: documentation of acetabular labrum tear\n6. Willingness to participate and ability to understand and sign informed consent document: ability to understand study and consent willingly\n7. Returning subjects enrolled in protocol 2017P001391\u002FPHS\n\nExclusion Criteria and Rationale:\n\n1. Non-English speaking subjects: PROMs are only validated in English.\n2. Systemic infection: surgery is generally contraindicated when systemic infection is present.\n3. Systemic heparinization: the vascularity of the bone and adjacent tissues is significant, posing a potential problem for bleeding when the patient is anti-coagulated.\n4. Pregnant women\u002Ffetuses: although surgery can be performed on pregnant women, pregnant women are excluded under federal regulations.",{"count":166,"type":22},400,"Femoro-acetabular impingement is a well known cause of damage to the acetabular labrum and chondrolabral junction. Additionally, it has been proposed that disruption of hip biomechanics resulting from a labral tear causes a faster progression towards osteoarthritis (OA). This progression has been observed to begin with breakdown of the chondrolabral junction with later development of diffuse osteoarthritis. Use of hip arthroscopy has increased dramatically in recent years to treat symptomatic labral tears and potentially avoid the morbidity and cost associated with hip osteoarthritis.\n\nCorrection of labral pathology presents a technical challenge and many techniques currently exist. Increased understanding of the structure-functional relationship dictated by labral anatomy has led to the development of methods aimed at restoring functional anatomy by re-establishing the labrum's native position and contour on the rim of the acetabulum. Therefore, akin to repairing a torn meniscus in the knee, restoring the anatomic footprint of a torn labrum will reconstitute normal joint biomechanics.\n\nDespite the advances in techniques for labral repair, strategies for mitigating or repairing damage to the chondrolabral junction do not yet exist. This area has been shown to consist of hyaline and fibro cartilage. Many techniques for cartilage repair exist, although most are not feasible due to technical challenges specific to the hip joint.\n\nThe management of articular cartilage defects is one of the most challenging clinical problems for orthopaedic surgeons. Articular cartilage has a limited intrinsic healing capacity, and pathology frequently results in gradual tissue deterioration. Currently, the standard surgical intervention for end-stage degenerative joint pathology is total joint replacement. Early surgical interventions for symptomatic cartilage lesions including cell based therapies such as autologous chondrocyte implantation (ACI), bone marrow aspirate concentrate (BMAC) implantation, or microfracture have been suggested to restore normal joint congruity and minimize further joint deterioration. Techniques such as ACI, which have been successfully used in the knee joint, have limited application in the hip due to the technical difficulties of open procedures.",[169,170,28,171,172],"Acetabular Labrum Tear","Femoro Acetabular Impingement","Bone Marrow Aspirate Concentrate","Mesenchymal Stromal Cell",[169,170,28,171,172,174,175,176,177,178],"Chondrolabral Junction","Osteoarthritis","Femoroacetabuloplasty","Hip Arthroscopy","BMAC","2025-10-24",{"date":181,"type":40},"2025-10-27",{"date":183,"type":40},"2019-09-06",{"date":185,"type":22},"2027-06-30",{"name":187,"class":107},"Massachusetts General Hospital",{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":4,"eligibilityCriteria":194,"healthyVolunteers":195,"sex":17,"minAge":85,"maxAge":57,"enrollmentInfo":196,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":201,"conditions":202,"keywords":204,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":4},"100584940","phase-1-eb-oc-for-the-treatment-of-focal-chondralosteochondral-defects-in-the-knee-100584940","NCT06895889","EB-OC for the Treatment of Focal Chondral\u002FOsteochondral Defects in the Knee","A Prospective, Randomized, Controlled, Open-label, First-in-human Phase I\u002FIIb Study to Evaluate the Safety and Efficacy of the EB-OC Graft in the Repair of Full Thickness Chondral\u002Fosteochondral Defects of the Knee","Inclusion Criteria:\n\n1. Subject is male or female, between 18 and 65 years of age\n2. Subject's body mass index (BMI) is ≤ 35 kg\u002Fm2.\n3. Subject has up to two symptomatic, full-thickness cartilage defects of the knee femoral condyle with or without bone involvement that are:\n\n   1. Located on the femoral condyles or femoral trochlea\n   2. Each between 0.75 and 3 cm2 in area on screening images as confirmed by an independent radiologist\n   3. Classified as International Cartilage Repair Society (ICRS) grade 3 or 4.\n   4. Has baseline Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain \\\u003C65 and KOOS Activities of Daily Life \\\u003C70.\n4. Subject is willing and able to provide informed consent and comply with study requirements.\n5. Subject agrees to actively participate in a strict rehabilitation protocol and follow-up program.\n6. For women of childbearing potential, subject must have a negative pregnancy test at Screening, cannot be lactating and must be willing to use adequate contraception throughout study participation.\n\n   Note: Adequate contraception methods will include the following: Abstinence, Oral Contraceptives, Barrier Methods (Condoms, IUD's), or surgical sterilization.\n7. Subject is willing to give up the use of narcotics for 6 months post-surgery and use and record alternative pain medications (e.g., acetaminophen, or narcotic analgesics, if prescribed).\n\nNote: Post-surgical use of aspirin for clot prevention and narcotics for immediate post-surgical pain are acceptable.\n\nExclusion Criteria:\n\n1. Lesions on the opposing surface of the tibia that are classified as ICRS grade 3 or 4.\n2. Lesions on the opposing surface of the patella that are classified as ICRS grade 3 or 4 if a trochlear defect is being treated.\n3. Any existing prosthetic implants in the index knee.\n4. History of knee surgery in the index knee within 6 months prior to screening.\n5. Has osteoarthritis of Kellgren-Lawrence Grade ≥3 as diagnosed on standing radiographs in the index knee.\n6. Known history of hypersensitivity to gentamicin, other aminoglycosides, or products of bovine origin.\n7. Inflammatory arthritis, inflammatory joint disease, or uncorrected congenital blood coagulation disorders.\n8. Current infection or history of infection in the index knee joint.\n9. Current skin infection of the index knee joint or skin infection of the index knee joint within the past 3 months.\n10. Osteochondral defect greater than 7 mm in depth.\n11. Avascular necrosis (AVN) or osteonecrosis (ON).\n12. Meniscus tears or defects that require concomitant or prior removal of \\>50% of meniscus in the index knee.\n13. Varus or valgus malalignment exceeding 5° in either knee.\n14. Need for corrective concomitant osteotomy (tibio-femoral or patellofemoral).\n15. Symptomatic musculoskeletal condition in the lower limbs that could impede efficacy measures in the target knee.\n16. Diagnosed musculoskeletal cancer or any diagnosed cancer, other than musculoskeletal if not on long term remission (e.g., at least 5 years or negative biopsy at last exam), except basal cell carcinoma.\n17. Clinically significant abnormalities in vital signs at the time of screening defined by\n\n    * Systolic BP \\>140 or \\\u003C90 mmHg or diastolic BP \\>90 or \\\u003C60 mmHg\n    * Pulse \\\u003C60 or \\>100 bpm\n    * Respiratory Rate \\\u003C9 or \\>20\n    * Temperature \\>99 °F\n18. Hemoglobin, platelet, white blood cell count, creatinine, aspartate aminotransferase (AST), and alanine aminotransferase (ALT), prothrombin time (PT), and partial thromboplastin time (PTT) below the lower limit of normal or above the upper limit of normal.\n19. Active infection (e.g., HIV, viral hepatitis, syphilis, cellulitis, respiratory infection, etc.).\n20. Alcohol and drug (including medication) abuse.\n21. Subjects with any contraindications to MR imaging.\n22. Participation in concurrent trials or in previous trial within 90 days of signing informed consent.\n\nIntra-Operative Exclusion Criteria\n\n1. Greater than 2 defects requiring treatment\n2. A symptomatic defect with greater than 5 mm of bone loss",true,{"count":197,"type":22},36,[199,200],"PHASE1","PHASE2","EB-OC is a tissue engineered osteochondral tissue graft comprising of a living tissue engineered cartilage layer attaching to a bone scaffold. The goal of this clinical trial is to learn about in the safety and efficacy of the EB-OC graft in participants who require repair of chondral\u002Fosteochondral defects of the knee. The main question it aims to answer is if the EB-OC graft works to regenerate osteochondral tissue comprising of native hyaline cartilage anchors to the regenerated bone. Participants will receive treatment of either the EB-OC Graft implantation in an arthrotomy procedure or abrasion chondroplasty. Researchers will compare results from the EB-OC graft to abrasion chondroplasty to assess overall safety and effectiveness.",[28,203],"Osteochondral Defect",[205,206,207,208,209],"Abrasion Chondroplasty","Focal Chondra","Osteochondral Defects","Orthobiologics","Cartilage regeneration","2025-03-19",{"date":212,"type":40},"2025-03-26",{"date":214,"type":22},"2026-01-01",{"date":216,"type":22},"2028-12-31",{"name":218,"class":47},"Epibone, Inc.",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":17,"minAge":85,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":230,"conditions":231,"keywords":232,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":157},"100516329","phase-3-effect-of-prp-ppp--bmac-on-functional-outcomes-following-hip-arthroscopy-for-acetabular-labral-pathologies-100516329","NCT06003101","Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies","Effect of Platelet-Rich Plasma, Platelet-Poor Plasma, & Bone Marrow Aspirate Concentrate Application on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies: A Prospective Randomized Controlled Trial","PRP; PPP; BMAC","Inclusion Criteria:\n\n* Age: \\> or equal to 18 years\n* Clinically indicated for hip arthroscopy (by the study PI) to address a labral pathology\n* Willingness to participate, amenable to randomization into either treatment arm of the research study, and the ability to understand \\& sign the informed consent document\n\nExclusion Criteria:\n\n* Non-English speaking (PROM surveys are only validated in English)\n* Prior same site (i.e., ipsilateral hip) surgery, including but not limited to previous hip arthroscopy, core decompression, or periacetabular osteotomies",{"count":228,"type":22},160,[25],"The goal of this clinical trial is to assess the effect of PRP\u002FPPP\u002FBMAC application on functional outcomes after hip arthroscopy to address acetabular labral pathologies. The main questions it aims to answer are:\n\n1. Does PRP\u002FPPP\u002FBMAC application improve functional outcomes after hip arthroscopy to address acetabular labral pathologies?\n2. Does PRP\u002FPPP\u002FBMAC application reduce the arthritic burden as measured by functional outcomes following hip arthroscopy to address labral pathologies with concomitant PRP\u002FPPP\u002FBMAC application?",[169,170,28,171],[169,170,28,171,174,175,177,178],"2024-11-18",{"date":235,"type":40},"2024-11-20",{"date":237,"type":40},"2023-08-30",{"date":239,"type":22},"2045-08-30",{"name":187,"class":107},{"id":242,"slug":243,"hasResults":11,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":248,"targetDuration":250,"studyType":88,"phases":4,"briefSummary":251,"conditions":252,"keywords":256,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":157},"100390469","knee-registry-knieregister-100390469","NCT04364334","Knee Registry (Knieregister)","Collecting Diagnostic, Treatment and Follow-up Data on Knee Treatments.","Inclusion Criteria:\n\n* Receives orthopaedic knee surgery or conservative knee treatment (advice, physiotherapy, injections etc) at the UMC Utrecht;\n* Able to read and understand Dutch language;\n* Is able and willing to signs the broad consent form.\n\nExclusion Criteria:\n\n* Receives no treatment (refusal of surgery or treatment);\n* Receives treatment elsewhere.",{"count":249,"type":22},1000000,"20 Years","Rationale: In view of patient care, patient characteristics and treatment parameters are registered for all patients visiting the Mobility Clinic of the University Medical Center Utrecht for orthopaedic knee treatment. Patients also fill out questionnaires for function, pain and mobility of the knee, before and after treatment.\n\nObjective: The main objective of this registry is to collect patient characteristics and treatment parameters together with data from the questionnaires in a database. This knee registry can be used for future research questions.\n\nStudy design: This is a longitudinal observational registry.\n\nStudy population: All patients that visit the Mobility Clinic will be asked to participate in the knee registry. Patients that meet one or more of the following criteria will be excluded: are below the age of 16, not able or willing to sign the broad consent form, not being able to read and understand Dutch language, or receiving medical treatment for their knee elsewhere.\n\nMain study parameters\u002Fendpoints: Data will be collected for future research for which the purpose is not known at this time. When new research will be conducted, study parameters will be set. A study application has to be submitted to the institutional ethical review board of the University Medical Center Utrecht. Patients do not need to be asked permission for the use of their data for each study individually. Only when additional information is needed.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: The burden for patients to participate in this registry is minimal and consists of time. Any future results may be beneficial for patients. Participation or refusal to participate in the registry has no consequences for their treatment.",[253,254,255,28,203],"Knee Pathology","Osteoarthritis, Knee","Osteochondritis Dissecans",[94],"2023-11-28",{"date":259,"type":40},"2023-12-05",{"date":261,"type":40},"2017-01",{"date":263,"type":22},"2100-01",{"name":265,"class":107},"UMC Utrecht"]